Ivan Bank
Corneal and Contact Management · Dallas, TXNPI 1194706861
Payments from drug & device makers
What this record shows
This record is dominated by gifts: $2,871 of the $4,400 with a category attached, or 65.2%. Visionary Optics LLC accounts for 65.2% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2024 at $1,141 and has fallen 50.6% since, to $564 in 2025.
Across 47 payments — averaging $93.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Visionary Optics LLC$3K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$378
- Bausch & Lomb Americas Inc.$313
- Novartis$188
- Coopervision Inc.$170
- Biotissue Holdings Inc.$136
- plus $343 from 8 others
What the payments were for
- Consulting fees$3007%
- Food & beverage$1,22928%
- Gifts$2,87165%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Visionary Optics LLC | 6 | $2,871 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $378 |
| Bausch & Lomb Americas Inc. | 6 | $313 |
| Novartis | 4 | $188 |
| Coopervision Inc. | 8 | $170 |
| Biotissue Holdings Inc. | 4 | $136 |
| Alcon | 5 | $96 |
| AbbVie(2 entities) | 3 | $77 |
| Synergeyes, Inc. | 1 | $67 |
| Oyster Point Pharma, Inc. | 1 | $32 |
| Johnson & Johnson Vision Care, Inc. | 1 | $24 |
| Tarsus Pharmaceuticals, Inc. | 1 | $23 |
| Eyevance Pharmaceuticals LLC | 1 | $13 |
| Glaukos Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MULTI-FOCAL LENS$300
- ZENLENS$125
- XIIDRA$125
How this compares
$4,400 in reported general payments places this provider in the 80th percentile of 103 corneal and contact management providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 26 | $299 |
Paid to pharmacies, not to this prescriber.
Other corneal and contact management in Dallas
- O DishmanDallas$4K
- Murray JohnsonDallas$3K
- Cuong PhamDallas$2K
- Maurice WilsonConroe$362K
- Roberto SaenzSan Antonio$171K
- Fariba ParmerGrapevine$26K
- Vissett SunHouston$13K
- Napoleon LoveroHouston$12K
- Sairah MalikHouston$10K
- Darlene JonesPlano$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.